

## **Association of Coronary Stenosis with Cerebral Small Vessel Diseases in Neurologically Asymptomatic Adults**

**(Short title : Coronary stenosis & cerebral small vessel diseases)**

Kyungha Min, MD<sup>a\*</sup>; Jae-Moon Yun, MD, MPH, PhD<sup>a\*</sup>; Seo Eun Hwang, MD, MPH<sup>a</sup>; Ki-Woong Nam, MD, MSc<sup>b</sup>; Han-Yeong Jeong, MD<sup>c</sup>; Hyung-Min Kwon, MD, PhD<sup>b\*\*</sup>; Jin-Ho Park, MD, MPH, PhD<sup>a\*\*</sup>

<sup>a</sup>Department of Family Medicine, Seoul National University College of Medicine and Seoul National University Hospital, Seoul, South Korea

<sup>b</sup>Department of Neurology, Seoul National University College of Medicine and Seoul Metropolitan Government-Seoul National University Boramae Medical Center, Seoul, South Korea

<sup>c</sup>Department of Neurology, Emergency Medical Center, Seoul National University College of Medicine and Seoul National University Hospital, Seoul, South Korea

\* Both authors contributed equally to this work as co-first authors.

\*\* H.-M.K. and J.-H.P. contributed equally as corresponding authors.

**Correspondence to:**

Jin-Ho Park, MD, MPH, PhD

Department of Family Medicine,

Seoul National University College of Medicine and Seoul National University Hospital,

101 Daehak-ro, Jongno-gu, Seoul 03080, South Korea

Tel.: +82-2-2072-0865

Fax: +82-2-766-3296

Email: [pjhn@snu.ac.kr](mailto:pjhn@snu.ac.kr)

Hyung-Min Kwon, MD, PhD

Department of Neurology,

Seoul National University College of Medicine and Seoul Metropolitan Government-Seoul

National University Boramae Medical Center

20 Boramae-ro 5-gil, Dongjak-gu, Seoul 07061, South Korea

Tel.: +82-2-870-2475

Fax: +82-2-831-2826

Email: [hmkwon@snu.ac.kr](mailto:hmkwon@snu.ac.kr)

**Key words:** cerebral small vessel diseases, silent lacunar infarction, cerebral microbleeds,  
white matter hyperintensity, coronary stenosis

**Total word count of the manuscript :** 4006 words

## Abstract

**Background:** The high prevalence of coronary stenosis in patients with stroke is well established. However, the association between coronary stenosis and cerebral small vessel diseases (cSVD) in asymptomatic populations remains unclear.

**Methods:** As a cross-sectional study, we evaluated South Korean adults who underwent a health checkup including brain magnetic resonance imaging and coronary computed tomography angiography between January 2010 and December 2013. The degree of coronary stenosis was classified into three groups: no stenosis (0%), non-significant stenosis (1–49%), and significant stenosis ( $\geq 50\%$ ). cSVD includes silent lacunar infarction (SLI), cerebral microbleeds (CMB), and white matter hyperintensity (WMH). We used binary logistic regression analyses for SLI and CMB, and linear regression analysis for WMH.

**Results:** A total of 1,571 participants were evaluated. The prevalence of non-significant and significant coronary stenosis was 369 (23.5%) and 95 (6.1%), respectively. The prevalence of SLI and CMB was 112 (7.1%) and 66 (4.2%), respectively. The mean WMH volume was  $2.6 \pm 6.1$  mL. SLI was significantly associated with both non-significant (adjusted odds ratio [aOR] = 1.94;  $p = 0.004$ ) and significant coronary stenosis (aOR = 2.37;  $p = 0.011$ ), even showing dose-response relationship ( $p$  for trend = 0.012). For WMH, only significant coronary stenosis was associated with WMH ( $\beta = 0.27$ ;  $p = 0.013$ ) and had a dose-response relationship ( $p$  for trend = 0.012).

**Conclusions:** The presence and severity of coronary stenosis were significantly associated with SLI and WMH. Physicians who detects any of coronary stenosis or cSVD should pay attention to the possible coexistence of the other disease.

## **Introduction**

Atherosclerotic cardiovascular disease (ASCVD) is a leading cause of death worldwide. According to the World Health Organization, an estimated 17.9 million people died from cardiovascular diseases (CVD), representing 32% of all global deaths in 2019. Of these, 85% were due to heart attack and stroke [1]. The burden of CVD in the number of disability-adjusted life years also continues to increase globally [2].

Stroke usually causes disabilities with limited neurological recovery; therefore, it is important to identify high-risk groups early, and manage modifiable risk factors [3]. Cerebral small vessel diseases (cSVD), which is a group of subclinical pathologies including silent lacunar infarction (SLI), cerebral microbleeds (CMB), and white matter hyperintensities (WMH), is known to lead to ischemic and hemorrhagic strokes [4]. Therefore, understanding the underlying mechanisms of cSVD development and its risk factors is essential for future stroke prevention.

The majority of patients with both nonfatal and sudden cardiac death do not experience any prior symptoms of chest pain or exertional dyspnea, highlighting the importance of early detection and treatment of underlying subclinical coronary atherosclerosis [5]. To date, growing evidence supports the use of noninvasive imaging tests to screen for coronary stenosis [6,7]. Coronary computed tomography angiography (CCTA) is an effective imaging technique that can identify plaque composition and the severity of coronary stenosis, and is increasingly accepted as a first-line test for the diagnosis of coronary artery disease [8]. Some studies have reported the effectiveness of CCTA screening for coronary artery disease in high-risk groups [9,10].

Several studies have shown a relationship between stroke and asymptomatic coronary stenosis, or cSVD and symptomatic coronary stenosis. The burden of asymptomatic coronary artery disease is high in patients with nonfatal cerebral infarction and unknown coronary heart disease [11]. Symptomatic coronary atherosclerosis is also a known risk factor for silent brain infarction [12]. Furthermore, significant associations between coronary artery calcification and cSVD in asymptomatic adults have also been reported [13]. Hence, we can assume that there may be a significant relationship between subclinical coronary stenosis and cSVD. However, to the best of our knowledge, no studies have investigated the relationship in neurologically and cardiologically asymptomatic screening populations. In South Korea, it is common to undergo health checkups using advanced imaging modalities such as brain magnetic resonance imaging (MRI) and CCTA. In this study, we aimed to evaluate the association between coronary stenosis and cSVD by using brain MRI and CCTA data in an asymptomatic screening population.

## **Methods**

### **Study Population**

We used a consecutive health checkup registry from the Seoul National University Hospital Health Promotion Center between January 2010 and December 2013. We retrospectively evaluated 1,627 subjects who underwent voluntary screening health checkups, including both brain MRI and concomitant CCTA. We excluded subjects who had reported a history of previous stroke, myocardial infarction, or angina (n=56). Finally, a total of 1,571 subjects who were neurologically and cardiologically asymptomatic were enrolled. This study was approved by the Institutional Review Board of the Seoul National University Hospital (IRB No. 1502-026-647). All experiments were performed in accordance with the Declaration of Helsinki and the relevant guidelines and regulations.

### **Evaluation of Coronary Stenosis**

CCTA was performed using a 64-slice dual-source CT scanner (Somatom Definition [Siemens Medical Solutions, Forchheim, Germany]). A computed tomography (CT) scan was performed using a retrospective ECG-gated mode with ECG pulsing. Scans were performed from the diaphragm to the level of tracheal bifurcation in the caudo-cranial direction. The means and ranges of the heart rates during CT scanning were recorded for all patients. The CT data was processed using a three-dimensional software (Rapidia [INFINITT, Seoul, Korea]), and the images were assessed by an experienced radiologist. The presence of coronary stenosis was evaluated semi-quantitatively and described as the greatest percentage of lumen diameter reduction among the three epicardial coronary arteries, including the left anterior descending artery, left circumflex artery, and right coronary artery (estimated as multiples of 5 %) [20,21]. If there was stenosis in two or more coronary arteries, the value

with the highest degree of stenosis was selected. In the current study, we classified coronary stenosis into three groups: no stenosis (0%), non-significant stenosis (1-49%), and significant stenosis ( $\geq 50\%$ ).

### **Evaluation of Cerebral Small Vessel Diseases**

In this study, we evaluated all three components of cSVD: SLI, CMB, and WMH. The methods used to measure cSVD have been described in detail in previous studies [14]. In brief, brain MRIs with 1.5- or 3-Tesla MR scanners (Signa [GE Healthcare, Milwaukee, WI, USA] or Magnetom Sonata scanners [Siemens, Munich, Germany]) were performed in all subjects, and their brain MRI data were evaluated for cSVD. A SLI was defined as a focal infarction that was 3-15 mm in size and in the territory of the perforating branches to the basal ganglia, thalamus, internal capsule, corona radiata, centrum semiovale, brain stem, or cerebellum, which had a central signal intensity corresponding to the cerebrospinal fluid on T1- and T2-weighted images in MRI examinations [15]. A CMB was defined as a focal round lesion less than 10 mm in size with a low signal on T2-gradient echo images [16] and WMH volume was measured using a computer-assisted semi-automated technique (MIPAV version 7.3.0. (National Institutes of Health, Bethesda, MD). All radiological markers were rated by two neurologists and disagreements were resolved by discussion with a third rater.

### **Clinical Variables**

We measured demographic factors and clinical cerebrovascular and cardiovascular risk factors that were collected during the health checkup. Anthropometric factors, including height and weight, were measured while participants wore a light gown in an overnight fasting state. Body mass index (BMI) was calculated as weight (kg) divided by the square of height ( $m^2$ ) and the waist circumference (WC) was measured at the midpoint between the

lowest rib margin and iliac crest in a standing position. Each participant's lifestyle and known medical conditions were investigated through structured questionnaires and interviews by a trained family physician. Smoking status was classified as non-smoker, ex-smoker, or current smoker. Regular exercise was defined as moderate or high-intensity exercise for 150 min or more per week [17]. Information collected regarding medical status included previously diagnosed comorbid conditions, including stroke or myocardial infarction/angina, and use of related medications (i.e., antihypertensives, antidiabetic drugs, lipid-lowering drugs, anti-platelet drugs, and anti-coagulants). Blood pressure (BP) was measured after 5 min of rest in the sitting position. We also evaluated laboratory examination results including: fasting blood glucose, hemoglobin A1c (HbA1c), total cholesterol, triglyceride, high-density lipoprotein cholesterol, and low-density lipoprotein cholesterol. We calculated the estimated glomerular filtration rate (eGFR) using the Modification of Diet in Renal Disease (MDRD) formula. All serum samples were obtained after fasting for over 12 hours. Subjects were considered to have hypertension if they had a high systolic ( $\geq 140$  mmHg) or diastolic ( $\geq 90$  mmHg) blood pressure or were currently being treated with antihypertensive medications. Diabetes mellitus (DM) was defined as a fasting blood glucose level of 126 mg/dL or more or HbA1c more than or equal to 6.5%, or a self-reported prior diagnosis of DM with current use of insulin or oral hypoglycemic medications. Dyslipidemia was defined as a total serum cholesterol level of more than or equal to 240 mg/dL or current use of lipid-lowering drugs.

### **Statistical analysis**

The data is presented as means (SDs) or number of subjects (percentages), as appropriate. We transformed the WMH volume into a square root scale because of the excessive number of zeroes [18]. Descriptive statistics were used to assess basic characteristics of the study population. To conduct univariate and multivariate analysis, we used binary logistic



regression analysis for SLI and CMB, and in the case of WMH, we conducted linear regression analysis. In the multivariate analysis, we included age, sex, BMI, smoking, exercise, hypertension, DM, and dyslipidemia as confounders because they are established cardiovascular risk factors [19]. According to previous studies, alcohol consumption was assumed to be a possible confounder [20]. Additionally, WC and eGFR were considered possible confounders because significant associations were observed in the univariate analyses. Therefore, we performed multivariate analyses adjusted for age, sex, BMI, WC, smoking, drinking, exercise, hypertension, DM, dyslipidemia, and eGFR. We also assessed the dose-response relationship between the degree of coronary stenosis and cSVD ( $p$  for trend). All statistical analyses in the current study were conducted using STATA version.16.1 (StataCorp, College Station, Texas, USA), and statistical significance was considered if the  $p$  value was less than 0.05.

## Results

We included a total of 1,571 neurologically and cardiologically asymptomatic participants (mean age, 56.7 years; female, 42.6%). Non-significant coronary stenosis was found in 369 (23.5%) participants, and significant coronary stenosis was observed in 95 (6.1%) participants. The prevalence of SLI and CMB were 112 (7.1%) and 66 (4.2%), respectively. The mean WMH volume was  $2.6 \pm 6.1$  ml. With regards to smoking status, 828 (52.7%) participants were non-smokers, 446 (28.4%) were ex-smokers, and 297 (18.9%) were current smokers. There were 593 (37.8%) participants who were regarded as having hypertension, 259 (16.5%) participants had DM, and 358 (22.8%) had dyslipidemia. The other detailed baseline characteristics of the study subjects are presented in Table 1.

In logistic regression analysis for SLI, non-significant coronary stenosis (adjusted odds ratio (aOR) = 1.94; 95% confidence interval (CI) = 1.23–3.05;  $p = 0.004$ ) and significant coronary stenosis (aOR = 2.37; 95% CI = 1.22–4.63;  $p = 0.011$ ) were found to be significantly associated with SLI after adjusting for possible confounders (Table 2). The severity of coronary stenosis was associated with an increasing trend in the prevalence of SLI ( $p$  for trend = 0.012).

In the logistic regression analysis for CMB, although both non-significant (aOR = 1.43) and significant coronary stenosis (aOR = 1.18) were associated with a higher prevalence of CMB, statistical significance was not achieved ( $p = 0.216$  and  $p = 0.728$ , respectively) (Table 3).

According to linear regression for WMH, only significant coronary stenosis ( $\beta = 0.27$ ; 95% CI = 0.06–0.48,  $p = 0.013$ ) was found to be statistically significant. They also showed dose-response relationships ( $p$  for trend = 0.012) (Table 4).

## Discussion

This study aimed to investigate the association between coronary stenosis and cSVD in neurologically asymptomatic adults. There was a significant correlation with SLI and both non-significant and significant coronary stenosis, whereas, only significant stenosis was associated with WMH. Dose-response relationships were also observed for SLI and WMH. However, there was no relationship between coronary stenosis and CMB.

The significant association observed between coronary stenosis and SLI/WMH may have resulted from several mechanisms. First, since coronary stenosis and SLI/WMH share cardiovascular risk factors, such as hypertension, dyslipidemia, DM, and smoking, they may share the same pathophysiology to atherosclerosis. Comparing the results of the univariate and multivariate analyses in this study, it was found that the OR was attenuated when the risk factors were adjusted, indicating that they had shared risk factors. To date, the exact underlying etiology of cSVD is not well understood [4], but several explanations have been proposed. According to previous studies [21], cSVD may be affected by different pathologies. The most common form of small vessel pathology results from microatheroma at the origin of perforated arterioles, similar to large-vessel atherosclerosis. Failure of the blood-brain barrier, which causes leakage of serum components into and through the walls of cerebral small vessels, resulting in neuronal and glial damage, has also been suggested as an important cause of SVD-related pathology. According to a study [22], CMB is generally considered to have two types of vascular pathological changes: hypertensive vasculopathy and cerebral amyloid angiopathy. CMB is less associated with atherosclerosis, which may explain why there was no relationship between coronary stenosis and CMB in this study. Second, endothelial dysfunction can cause a breakdown of the blood-brain barrier, resulting

in perivascular tissue and arteriolar wall damage, which is considered important in coronary stenosis and SLI/WMH [4,23,24]. Third, oxidative stress resulting in chronic inflammation can lead to coronary stenosis and SLI/WMHs. Previous studies have shown that various noxious stimuli that induce vascular oxidative stress have been implicated in the pathogenesis of various disease states, including stroke [25] and coronary artery disease [26]. Fourth, environmental factors such as air pollution can lead to coronary stenosis and cSVD. One study suggested that increased exposure to air pollution is associated with cSVD [27] and coronary stenosis [28]. Additionally, genetic factors can also cause coronary stenosis [29] and cSVD [30].

In previous studies, researchers evaluated cSVD in patients with coronary artery diseases, such as myocardial infarction or angina. However, several studies have reported the prevalence of coronary artery disease in stroke patients. Uekita et al. showed that the prevalence of SLI was significantly greater in two- and three-vessel coronary artery disease groups than in zero- and one-vessel groups [31]. Hur et al. investigated 317 ischemic stroke patients with no known coronary heart disease and found that 48% of the patients had significant coronary stenosis [32]. However, until now, there has been a lack of research on the association between cSVD and coronary stenosis in neurologically and cardiologically asymptomatic populations. In addition to the above studies, our findings add strong evidence to the association between SLI/WMH and asymptomatic coronary stenosis. To the best of our knowledge, our study is the first to be conducted in a general screening population with a relatively large sample size. We also considered various risk factors, including lifestyle and disease factors, which may affect both cSVD and coronary stenosis.

The current study has several limitations. First, as a cross-sectional study, it could not prove causality between coronary stenosis and SLI/WMH. Therefore, careful interpretation is required. Second, because our study population was based on a health checkup registry,

there may be potential for selection bias. Although our checkup center is one of the largest in South Korea and covers a nationwide population, our results need to be validated by population-based prospective cohort studies. Lastly, some subjects might have been taking medications that affect cSVD or coronary stenosis. In this study, we aimed to evaluate neurologically asymptomatic subjects and excluded subjects who experienced stroke or myocardial infarction/angina based on structured questionnaire results. Despite the exclusion criteria, there may be hidden effects from subjects taking antiplatelet and anticoagulant agents (i.e., aspirin, warfarin, clopidogrel, and other antithrombotic agents). If someone is neurologically asymptomatic, but takes one of these drugs for other reasons, such as atrial fibrillation or primary prevention for ASCVD, the underlying mechanism may be affected. Therefore, we conducted an additional analysis excluding 180 participants who were taking antithrombotic agents. This yielded the same results as the main analysis presented above **(Supp Table1)**.

Since coronary stenosis and SLI/WMH are closely related and share an underlying mechanism, people with SLI/WMH should be cautious about coronary artery disease and vice versa. Furthermore, individuals with SLI/WMH or coronary stenosis require appropriate management to prevent disease progression. It is necessary to manage risk factors and plan screening tests for high-risk groups for early detection. In particular, cSVD and coronary stenosis are treated by different specialists; therefore, they should be comprehensively managed.

In this study, we investigated the association between coronary stenosis and cSVD in neurologically and cardiologically asymptomatic adults. We found that both non-significant and significant coronary stenosis was associated with SLI and only significant stenosis was associated with WMH. Therefore, physicians who discover coronary stenosis or cSVD need to pay attention to the possible coexistence of the other disease, manage shared risk factors,

and consider screening tests for the other diseases for early detection and management.

**Acknowledgements:** None

**Sources of Funding:** None

**Disclosures:** This paper followed the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement [33].

## References

- [1] World Health Organization, Cardiovascular diseases (CVDs) Fact sheet, 2021. <http://www.who.int/mediacentre/factsheets/fs317/en/>.
- [2] G.A. Roth, G.A. Mensah, C.O. Johnson, et al, Global burden of cardiovascular diseases and risk factors, 1990–2019: update from the GBD 2019 study, *J. Am. Coll. Cardiol.* 76 (2020) 2982–3021. <https://doi.org/10.1016/j.jacc.2020.11.010>.
- [3] B.J. Kim, S.H. Lee, Prognostic impact of cerebral small vessel disease on stroke outcome, *J. Stroke.* 17 (2015) 101–110. <https://doi.org/10.5853/jos.2015.17.2.101>.
- [4] J.M. Wardlaw, C. Smith, M. Dichgans, Small vessel disease: mechanisms and clinical implications, *Lancet Neurol.* 18 (2019) 684–696. [https://doi.org/10.1016/S1474-4422\(19\)30079-1](https://doi.org/10.1016/S1474-4422(19)30079-1).
- [5] R.J. Myerburg, A. Interian Jr, R.M. Mitrani, K.M. Kessler, A. Castellanos, Frequency of sudden cardiac death and profiles of risk, *Am. J. Cardiol.* 80 (1997) 10f–19f. [https://doi.org/10.1016/s0002-9149\(97\)00477-3](https://doi.org/10.1016/s0002-9149(97)00477-3).
- [6] E.K. Choi, S.I. Choi, J.J. Rivera, et al, Coronary computed tomography angiography as a screening tool for the detection of occult coronary artery disease in asymptomatic individuals, *J. Am. Coll. Cardiol.* 52 (2008) 357–365. <https://doi.org/10.1016/j.jacc.2008.02.086>.
- [7] I. Cho, S.J. Al’Aref, A. Berger, et al, Prognostic value of coronary computed tomographic angiography findings in asymptomatic individuals: a 6-year follow-up from the prospective multicentre international CONFIRM study, *Eur. Heart J.* 39 (2018) 934–941. <https://doi.org/10.1093/eurheartj/ehx774>.
- [8] K.M. Abdelrahman, M.Y. Chen, A.K. Dey, et al, Coronary computed tomography angiography from clinical uses to emerging technologies: JACC state-of-the-art review, *J. Am.*

Coll. Cardiol. 76 (2020) 1226–1243. <https://doi.org/10.1016/j.jacc.2020.06.076>.

[9] J.B. Muhlestein, D.L. Lappé, J.A. Lima, et al, Effect of screening for coronary artery disease using CT angiography on mortality and cardiac events in high-risk patients with diabetes: the FACTOR-64 randomized clinical trial, JAMA. 312 (2014) 2234–2243. <https://doi.org/10.1001/jama.2014.15825>.

[10] J.J. Bax, L.H. Young, R.L. Frye et al., Screening for coronary artery disease in patients with diabetes, Diabetes Care. 30 (2007) 2729–2736. <https://doi.org/10.2337/dc07-9927>.

[11] P. Amarenco, P.C. Lavallée, J. Labreuche, et al, Prevalence of coronary atherosclerosis in patients with cerebral infarction, Stroke. 42 (2011) 22–29. <https://doi.org/10.1161/STROKEAHA.110.584086>.

[12] H. Tanaka, K. Sueyoshi, M. Nishino, M. Ishida, R. Fukunaga, H. Abe, Silent brain infarction and coronary artery disease in Japanese patients, Arch. Neurol. 50 (1993) 706–709. <https://doi.org/10.1001/archneur.1993.00540070026009>.

[13] B.J. Kim, S.H. Lee, C.K. Kim, et al, Advanced coronary artery calcification and cerebral small vessel diseases in the healthy elderly, Circ. J.. 75 (2011) 451–456. <https://doi.org/10.1253/circj.cj-10-0762>.

[14] K.W. Nam, H.M. Kwon, H.Y. Jeong, J.H. Park, H. Kwon, S.M. Jeong, Serum homocysteine level is related to cerebral small vessel disease in a healthy population, Neurology. 92 (2019) e317–e325. <https://doi.org/10.1212/WNL.0000000000006816>.

[15] J.E. Lee, D.W. Shin, J.M. Yun, et al, Insulin resistance is a risk factor for silent lacunar infarction, Stroke. 47 (2016) 2938–2944. <https://doi.org/10.1161/STROKEAHA.116.014097>.

[16] J.M. Wardlaw, E.E. Smith, G.J. Biessels, et al, Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration, Lancet Neurol. 12 (2013) 822–838. [https://doi.org/10.1016/S1474-4422\(13\)70124-8](https://doi.org/10.1016/S1474-4422(13)70124-8).



- [17] R.H. Eckel, J.M. Jakicic, J.D. Ard, et al., 2013 AHA/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines, *Circulation*. 129 Supplement 2 (2014) S76–S99. <https://doi.org/10.1161/01.cir.0000437740.48606.d1>.
- [18] K.W. Nam, H.M. Kwon, H.Y. Jeong, et al, Cerebral white matter hyperintensity is associated with intracranial atherosclerosis in a healthy population, *Atherosclerosis*. 265 (2017) 179–183. <https://doi.org/10.1016/j.atherosclerosis.2017.09.010>.
- [19] R. Padwal, S.E. Straus, F.A. McAlister, Cardiovascular risk factors and their effects on the decision to treat hypertension: evidence based review, *BMJ*. 322 (2001) 977–980. <https://doi.org/10.1136/bmj.322.7292.977>.
- [20] F. Rincon, C.B. Wright, Current pathophysiological concepts in cerebral small vessel disease, *Front. Aging Neurosci*. 6 (2014) 24. <https://doi.org/10.3389/fnagi.2014.00024>.
- [21] R.A.R. Gons, Vascular Risk Factors in Cerebral Small Vessel Disease. A Diffusion Tensor Imaging Study: [sl: sn], 2012.
- [22] S.M. Greenberg, M.W. Vernooij, C. Cordonnier, et al, Cerebral microbleeds: a guide to detection and interpretation, *Lancet Neurol*. 8 (2009) 165–174. [https://doi.org/10.1016/S1474-4422\(09\)70013-4](https://doi.org/10.1016/S1474-4422(09)70013-4).
- [23] A. Hassan, B.J. Hunt, M. O’Sullivan, et al, Markers of endothelial dysfunction in lacunar infarction and ischaemic leukoaraiosis, *Brain*. 126 (2003) 424–432. <https://doi.org/10.1093/brain/awg040>.
- [24] E. Gutiérrez, A.J. Flammer, L.O. Lerman, J. Elízaga, A. Lerman, F. Fernández-Avilés, Endothelial dysfunction over the course of coronary artery disease, *Eur. Heart J*. 34 (2013) 3175–3181. <https://doi.org/10.1093/eurheartj/eh351>.
- [25] J.P. Fanning, A.J. Wesley, A.A. Wong, J.F. Fraser, Emerging spectra of silent brain

- infarction, *Stroke*. 45 (2014) 3461–3471. <https://doi.org/10.1161/STROKEAHA.114.005919>.
- [26] T. Vichova, Z. Motovska, Oxidative stress: predictive marker for coronary artery disease, *Exp. Clin. Cardiol.* 18 (2013) e88–e91.
- [27] R. Maheswaran, T. Pearson, S.D. Beevers, M.J. Campbell, C.D. Wolfe, Air pollution and subtypes, severity and vulnerability to ischemic stroke—a population based case-crossover study, *PLOS ONE*. 11 (2016) e0158556. <https://doi.org/10.1371/journal.pone.0158556>.
- [28] N. Koyratty, Z. Hou, C. Huang, B. Lu, M. Wang, Association between long-term exposure to ambient air pollution and lesion ischemia in atherosclerotic patients, Abstracts. ISEE Conference, 2021.
- [29] S.M.B. Tabei, S. Senemar, B. Saffari, Z. Ahmadi, S. Haqparast, Non-modifiable factors of coronary artery stenosis in late onset patients with coronary artery disease in Southern Iranian population, *J. Cardiovasc. Thorac. Res.* 6 (2014) 51–55. <https://doi.org/10.5681/jcvtr.2014.010>.
- [30] C. Haffner, R. Malik, M. Dichgans, Genetic factors in cerebral small vessel disease and their impact on stroke and dementia, *J. Cereb. Blood Flow Metab.* 36 (2016) 158–171. <https://doi.org/10.1038/jcbfm.2015.71>.
- [31] K. Uekita, N. Hasebe, N. Funayama, et al, Cervical and intracranial atherosclerosis and silent brain infarction in Japanese patients with coronary artery disease, *Cerebrovasc. Dis.* 16 (2003) 61–68. <https://doi.org/10.1159/000070117>.
- [32] J. Hur, K.H. Lee, S.R. Hong, et al, Prognostic value of coronary computed tomography angiography in stroke patients, *Atherosclerosis*. 238 (2015) 271–277. <https://doi.org/10.1016/j.atherosclerosis.2014.10.102>.

[33] Von Elm, Erik, et al. "The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies." *The Lancet* 370.9596 (2007): 1453-1457.

## **Table legends**

Table 1. Baseline characteristics of subjects.

Table 2. Simple and multiple logistic regression analysis between possible predictors and silent lacunar infarction.

Table 3. Simple and multiple logistic regression analysis between possible predictors and cerebral microbleeds.

Table 4. Simple and multiple linear regression analysis between possible predictors and white matter hyperintensity.

Sup Table 1. Multiple logistic/linear regression between possible predictors and lacunar infarction/cerebral microbleeds/white matter hyperintensity excluding antithrombotic agents.

## Tables

Table 1. Baseline characteristics of subjects (n=1,571)

Sex, female	669 (42.6)
Age, year	56.7 (9.1)
Smoking status	
Non-smoker	828 (52.7)
Ex-smoker	446 (28.4)
Current smoker	297 (18.9)
Current drinking	778 (49.5)
Regular exercise	546 (34.8)
Body mass index (kg/m <sup>2</sup> )	24.3 (3.0)
Waist circumference (cm)	86.5 (8.7)
Systolic blood pressure (mmHg)	125.3 (15.4)
Diastolic blood pressure (mmHg)	75.5 (10.8)
Fasting glucose (mg/dl)	97.0 (22.9)
HbA1c (%)	5.9 (0.8)
Total cholesterol (mg/dl)	200.0 (35.8)
Triglyceride (mg/dl)	114.9 (69.4)
High density lipoprotein cholesterol (mg/dl)	54.2 (13.8)
Low density lipoprotein cholesterol (mg/dl)	128.2 (34.8)
eGFR(ml/min/1.73m <sup>2</sup> )	81.5 (14.8)
Hypertension	593 (37.8)
Diabetes Mellitus	259 (16.5)
Dyslipidemia	358 (22.8)
Taking Anti-coagulation or Anti-platelet Drugs	180 (11.4)
Coronary artery stenosis	
None	1107 (70.5)
Non-significant (1~49%)	369 (23.5)
Significant (≥50%)	95 (6.1)
SLI	112 (7.1)
CMB	66 (4.2)
WMH volume	2.6 (6.1)

Abbreviations : HbA1c, hemoglobin A1c; eGFR, estimated glomerular filtration rate; SLI, silent lacunar infarction; CMB, cerebral microbleeds; WMH, white matter hyperintensity

Data is presented as means (standard deviations) or number of subjects (percentages), as appropriate

Table 2. Simple and multiple logistic regression analysis between possible predictors and silent lacunar infarction

	Univariate analysis		Multivariate analysis	
	OR (95% CI)	<i>p</i> -value	OR (95% CI)	<i>p</i> -value
Coronary artery stenosis				
None	1 (ref)		1 (ref)	
Non-significant (1~49%)	3.15 (2.07 to 4.79)	<0.001	1.94 (1.23 to 3.05)	0.004
Significant (≥50%)	4.37 (2.38 to 8.04)	<0.001	2.37 (1.22 to 4.63)	0.011
<i>p</i> for trend		<0.001		0.012
Age				
Age	1.10 (1.07 to 1.13)	<0.001	1.08 (1.05 to 1.11)	<0.001
Female				
Female	0.86 (0.58 to 1.28)	0.464	1.41 (0.74 to 2.67)	0.300
Smoking status				
Non-smoker	1 (ref)		1 (ref)	
Ex-smoker	1.17 (0.76 to 1.82)	0.474	0.92 (0.49 to 1.72)	0.793
Current smoker	1.05 (0.62 to 1.76)	0.857	1.20 (0.61 to 2.38)	0.597
Current drinking				
Current drinking	1.10 (0.75 to 1.62)	0.619	1.57 (0.99 to 2.49)	0.054
Regular exercise				
Regular exercise	0.84 (0.56 to 1.28)	0.419	0.93 (0.60 to 1.43)	0.730
Body mass index (kg/m <sup>2</sup> )				
Body mass index (kg/m <sup>2</sup> )	1.04 (0.98 to 1.11)	0.225	0.93 (0.81 to 1.06)	0.286
Waist circumference (cm)				
Waist circumference (cm)	1.03 (1.01 to 1.06)	0.003	1.04 (0.99 to 1.10)	0.085
Hypertension				
Hypertension	2.86 (1.93 to 4.25)	<0.001	2.01 (1.32 to 3.07)	0.001
Diabetes Mellitus				
Diabetes Mellitus	2.39 (1.56 to 3.66)	<0.001	1.30 (0.82 to 2.06)	0.272
Dyslipidemia				
Dyslipidemia	1.26 (0.82 to 1.95)	0.296	0.98 (0.61 to 1.55)	0.918
eGFR(ml/min/1.73m <sup>2</sup> )				
eGFR(ml/min/1.73m <sup>2</sup> )	0.98 (0.97 to 1.00)	0.019	1.00 (0.99 to 1.01)	0.704

Abbreviations : eGFR, estimated glomerular filtration rate

Table 3. Simple and multiple logistic regression analysis between possible predictors and cerebral microbleeds

	Univariate analysis		Multivariate analysis	
	OR (95% CI)	<i>p</i> -value	OR (95% CI)	<i>p</i> -value
Coronary artery stenosis				
None	1 (ref)		1 (ref)	
Non-significant (1~49%)	2.07 (1.22 to 3.52)	0.007	1.43 (0.81 to 2.54)	0.216
Significant (≥50%)	2.01 (0.82 to 4.89)	0.126	1.18 (0.46 to 3.07)	0.728
<i>p</i> for trend		0.126		0.703
Age	1.05 (1.02 to 1.08)	0.001	1.04 (1.01 to 1.08)	0.011
Female	0.66 (0.39 to 1.12)	0.123	0.77 (0.35 to 1.69)	0.512
Smoking status				
Non-smoker	1 (ref)		1 (ref)	
Ex-smoker	1.33 (0.76 to 2.33)	0.312	0.87 (0.41 to 1.82)	0.709
Current smoker	1.18 (0.61 to 2.28)	0.630	0.96 (0.42 to 2.20)	0.929
Current drinking	1.50 (0.91 to 2.47)	0.114	1.68 (0.95 to 2.96)	0.075
Regular exercise	0.87 (0.51 to 1.48)	0.609	0.88 (0.52 to 1.52)	0.656
Body mass index (kg/m <sup>2</sup> )	0.97 (0.89 to 1.05)	0.405	0.97 (0.82 to 1.16)	0.769
Waist circumference (cm)	1.00 (0.97 to 1.03)	0.929	0.99 (0.93 to 1.05)	0.685
Hypertension	2.48 (1.50 to 4.10)	<0.001	2.16 (1.27 to 3.65)	0.004
Diabetes Mellitus	2.13 (1.23 to 3.70)	0.007	1.61 (0.89 to 2.89)	0.113
Dyslipidemia	0.74 (0.39 to 1.41)	0.364	0.64 (0.33 to 1.23)	0.184
eGFR(ml/min/1.73m <sup>2</sup> )	1.00 (0.98 to 1.01)	0.635	1.00 (0.99 to 1.02)	0.707

Abbreviations : eGFR, estimated glomerular filtration rate

Table 4. Simple and multiple linear regression analysis between possible predictors and white matter hyperintensity\*

	Univariate analysis		Multivariate analysis	
	$\beta$ (95% CI)	<i>p</i> -value	$\beta$ (95% CI)	<i>p</i> -value
Coronary artery stenosis				
None	1 (ref)		1 (ref)	
Non-significant (1~49%)	0.35 (0.22 to 0.47)	<0.001	-0.02 (-0.14 to 0.11)	0.800
Significant ( $\geq$ 50%)	0.72 (0.49 to 0.94)	<0.001	0.27 (0.06 to 0.48)	0.013
<i>p</i> for trend		<0.001		0.012
Age	0.06 (0.05 to 0.06)	<0.001	0.05 (0.05 to 0.06)	<0.001
Female	-0.09 (-0.20 to 0.02)	0.094	0.02 (-0.13 to 0.16)	0.847
Smoking status				
Non-smoker	1 (ref)		1 (ref)	
Ex-smoker	0.22 (0.09 to 0.34)	0.001	0.15 (0.01 to 0.30)	0.041
Current smoker	-0.07 (-0.22 to 0.07)	0.331	0.14 (-0.03 to 0.30)	0.098
Current drinking	-0.10 (-0.21 to 0.01)	0.072	0.05 (-0.06 to 0.16)	0.359
Regular exercise	-0.12 (-0.24 to -0.01)	0.038	-0.11 (-0.21 to -0.01)	0.040
Body mass index (kg/m <sup>2</sup> )	-0.01 (-0.03 to 0.01)	0.168	-0.02 (-0.05 to 0.01)	0.190
Waist circumference (cm)	0.00 (-0.00 to 0.01)	0.203	0.00 (-0.01 to 0.01)	0.748
Hypertension	0.43 (0.32 to 0.54)	<0.001	0.24 (0.14 to 0.35)	<0.001
Diabetes Mellitus	0.43 (0.29 to 0.58)	<0.001	0.14 (0.00 to 0.27)	0.050
Dyslipidemia	0.01 (-0.12 to 0.14)	0.846	-0.13 (-0.24 to -0.01)	0.035
eGFR(ml/min/1.73m <sup>2</sup> )	-0.01 (-0.01 to -0.00)	<0.001	-0.00 (-0.00 to 0.00)	0.681

Abbreviations : eGFR, estimated glomerular filtration rate

\*These variables were transformed into square root scales.



Sup Table 1. Multiple logistic/linear regression between possible predictors and silent lacunar

	SLI		CMB		WMH	
	OR (95% CI)	<i>p</i> -value	OR (95% CI)	<i>p</i> -value	$\beta$ (95% CI)	<i>p</i> -value
Coronary artery stenosis						
None	1 (ref)		1 (ref)		1 (ref)	
Non-significant (1~49%)	1.95 (1.18 to 3.24)	0.010	1.78 (0.94 to 3.36)	0.077	0.03 (-0.10 to 0.15)	0.692
Significant ( $\geq 50\%$ )	2.24 (1.04 to 4.82)	0.040	1.50 (0.52 to 4.32)	0.453	0.26 (0.04 to 0.48)	0.022
Age	1.09 (1.06 to 1.13)	<0.001	1.04 (1.00 to 1.08)	0.047	0.05 (0.04 to 0.06)	<0.001
Female	1.19 (0.58 to 2.42)	0.633	0.82 (0.34 to 1.95)	0.651	-0.01 (-0.16 to 0.15)	0.924
Smoking status						
Non-smoker	1 (ref)		1 (ref)		1 (ref)	
Ex-smoker	0.84 (0.42 to 1.67)	0.620	0.71 (0.31 to 1.61)	0.408	0.10 (-0.05 to 0.26)	0.179
Current smoker	1.12 (0.52 to 2.38)	0.778	1.06 (0.45 to 2.50)	0.899	0.15 (-0.02 to 0.31)	0.076
Current drinking	1.51 (0.91 to 2.51)	0.112	1.97 (1.04 to 3.72)	0.037	0.05 (-0.06 to 0.16)	0.376
Regular exercise	0.93 (0.57 to 1.50)	0.752	0.94 (0.52 to 1.70)	0.835	-0.14 (-0.25 to -0.04)	0.008
Body mass index (kg/m <sup>2</sup> )	0.89 (0.76 to 1.04)	0.155	0.87 (0.71 to 1.07)	0.190	-0.02 (-0.05 to 0.01)	0.245
Waist circumference (cm)	1.05 (0.99 to 1.11)	0.105	1.02 (0.95 to 1.09)	0.579	0.00 (-0.01 to 0.01)	0.958
Hypertension	2.29 (1.44 to 3.64)	<0.001	1.97 (1.11 to 3.52)	0.021	0.23 (0.12 to 0.33)	<0.001
Diabetes Mellitus	1.27 (0.74 to 2.17)	0.388	1.56 (0.79 to 3.08)	0.202	0.17 (0.02 to 0.32)	0.023
Dyslipidemia	1.30 (0.78 to 2.15)	0.311	0.64 (0.30 to 1.34)	0.233	-0.13 (-0.25 to -0.01)	0.031
eGFR(ml/min/1.73m <sup>2</sup> )	1.00 (0.99 to 1.01)	0.867	1.00 (0.98 to 1.02)	0.797	0.00 (-0.00 to 0.00)	0.846

infarction/cerebral microbleeds/white matter hyperintensity\* excluding antithrombotic agents

Abbreviations : eGFR, estimated glomerular filtration rate; SLI, silent lacunar infarction; CMB, cerebral microbleeds; WMH, white matter hyperintensity

\*These variables were transformed into square root scales.

